ClinicalTrials.gg
CompletedNCT04079413Updated Jul 23, 2020

Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients

A Phase 3 interventional study of GP40071 and NovoRapid® Penfill® in Diabetes and Diabetes Mellitus, Type 1, sponsored by Geropharm. Completed at 14 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-23.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Geropharm · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2019, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.

Enrollment
21st of 87
264 · median 50
Started
2019
with 6 others
Phase 3
24 of 87
none open now
Registered
80th of 87
by date
Lead sponsor
1 of 87
Geropharm

Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is one of 7 that started in 2019, is one of 24 in phase 3, and was the 80th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is a multi-center, open-label, randomized, parallel group trial in adult patients with T1DM comparing the efficacy and safety of GP40071 (insulin aspart, GEROPHARM) with that of NovoRapid®.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

Keywords

  • Insulin
  • Insulin aspart
  • Aspart
04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 264 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Geropharm is the lead sponsor of 23 studies on the registry; none are open to participants now.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written consent
  • Diabetes mellitus type 1 for at least 12 months prior to screening
  • History of basis-bolus (multiple dose injection (MDI)) therapy in stable doses at least 30 days
  • (HbA1c) level of 7.1 to 12.0 % at screening (both values inclusive)
  • (BMI) of 18.5 to 35 kg/m2 at screening (both values inclusive)
  • Subject is able and willing to comply with the requirements of the study protocol

Exclusion criteria

Exclusion Criteria:

  • to the use of insulin aspart
  • Insulin resistance over 1.5 U/kg insulin pro day
  • Change INN of insulin for 6 months prior to randomisation
  • History of treatment any biosimilar insulin for 6 months prior to randomisation (excl. GEROPHARM's insulins)
  • History of treatment any experimental drugs or medical devices for 3 months prior to randomisation
  • History of treatment insulin pump for 180 days prior to signed written consent or indication for use insulin pump
  • Presence of severe diabetes complications
  • History of severe hypoglycemia for 6 months prior to screening
  • History of 15 or more episodes mild hypoglycemia for 1 month prior to screening
  • History or presence of uncontrolled diabetes mellitus for 6 months prior to screening
  • History of administration of (14 days or more) for 1 year prior to screening
  • Administration of any drugs (Cyclosporine, Methotrexate, Rituximab, etc.)
  • History of vaccination for 6 months prior to randomisation
  • History of disease, except vitiligo and controlled autoimmune polyglandular syndrome (APS) types 1-3, except adrenal insufficiency
  • History of unstable angina, myocardial infarction, severe arrhythmia, heart failure III or IV for 1 year prior to screening
  • History of stroke or for 6 months prior to screening
  • History of to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions
  • Pregnant and breast-feeding women
  • Acute inflammation disease for 3 weeks prior to screening
  • Deviation of the laboratory results conducted during the screening:

value \< 9,0 g/dl; Hematocrit value \< 30 %; and AST value > 2 folds as high as maximal normal value; Serum value > 1.5 folds as high as maximal normal value

  • History of hematological disorders that can affect the reliability of estimation (hemoglobinopathies, hemolytic anemia, etc.)
  • Serious blood loss for 3 months prior to screening (blood donation, surgery procedure, etc.)
  • Incomplete recovery after surgery procedure
  • History of drug, alcohol abuse for 3 years prior to screening
  • Serological evidence of (HIV), (HbSAg), (HCVAb) or syphilis (Treponema pallidum) antibodies at screening
  • History of oncological disease during 5 years prior to screening
  • History of transplantation, except 3 months after corneal transplant
  • History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study
  • Inability follow to protocol
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
264 participants (actual)

Study arms

  • Experimental
    GP40071

    Subcutaneous (SC), before meals intake, up to Week 26

    Drug: GP40071

  • Active comparator
    NovoRapid® Penfill®

    Subcutaneous (SC), before meals intake, up to Week 26

    Drug: NovoRapid® Penfill®

Interventions

  • GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.

    Also known as: Insulin aspart

  • NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.

    Also known as: Insulin aspart

07

What researchers measure

Primary outcomes

  1. Immunogenicity

    Change from baseline in titer of antibodies to human insulin

    Time frame: 26 weeks

Secondary outcomes

  1. Glycated hemoglobin

    Change in HbA1c from baseline

    Time frame: 26 weeks

  2. Adverse Events frequency and degree

    Hypoglycemic episodes (glucose level \< 3.9 mmol/l) frequency; Occurrence of local reactions at injection sites; Occurrence allergic reactions

    Time frame: 26 weeks

  3. Fasting Plasma Glucose Level

    Change in fasting plasma glucose level from baseline

    Time frame: 26 weeks

  4. Seven-Point Glucose Testing

    Change in seven-point glucose testing results from baseline

    Time frame: 26 weeks

  5. Total Insulin Dose

    Change in total insulin dose per body weight (U/kg) from baseline

    Time frame: 26 weeks

  6. Body Mass Index

    Change in BMI from baseline

    Time frame: 26 weeks

  7. Treatment Satisfaction

    Change in treatment satisfaction from baseline. The total score DTSQ (The Diabetes Treatment Satisfaction Questionnaire) (range 0-36). Questions 1, 4, 5, 6, 7 and 8 assesses treatment satisfaction (summed these 6 questions). Questions 2 and 3 assess the burden from hyper- and hypoglycemia.

    Time frame: 26 weeks

  8. Achievement of Glycated Hemoglobin Goals

    The frequency of achievement glycated hemoglobin goals

    Time frame: 26 weeks

  9. Achievement of Glycated Hemoglobin < 7%

    The frequency of achievement glycated hemoglobin \< 7% ( 7% inclusive)

    Time frame: 26 weeks

08

Study locations

14 sites
  • Arkhangelsk Regional Clinical Hospital
    Arkhangel'sk, 163045, Russian Federation
  • Kazan Endocrinology Dispensary
    Kazan, 420073, Russian Federation
  • Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
    Krasnoyarsk, 660022, Russian Federation
  • Endocrinology Research Centre (Moscow)
    Moscow, 117036, Russian Federation
  • Rostov State Medical University
    Rostov-on-Don, 344022, Russian Federation
  • Polyclinic Сomplex
    Saint Petersburg, 190013, Russian Federation
  • City Diagnostic Center № 1
    Saint Petersburg, 194354, Russian Federation
  • City Polyclinic № 117
    Saint Petersburg, 194358, Russian Federation
  • EosMed
    Saint Petersburg, 195197, Russian Federation
  • Institute of Medical Research
    Saint Petersburg, 196084, Russian Federation
  • Almazov National Medical Research Centre
    Saint Petersburg, 197341, Russian Federation
  • Pokrovskaya Municipal Hospital
    Saint Petersburg, 199106, Russian Federation
  • Diabetes Center
    Samara, 443067, Russian Federation
  • Clinical City Hospital № 9
    Saratov, 410030, Russian Federation
09

References and documents

Publications

  • Karonova TL, Mayorov AY, Magruk MA, Zyangirova ST, Grigoryeva IV, Khmelnitski OK, Myshkovets A, Parfenova TM, Mosikian AA, Drai RV. Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid(R) Penfill(R)) in Type 1 diabetes mellitus. J Comp Eff Res. 2021 Jun;10(9):763-775. doi: 10.2217/cer-2020-0208. Epub 2021 Apr 30. PubMed 33928797 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jan 2020, 7 months.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 7 months is below that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2019
First posted
Sep 6, 2019
StartActual
Jun 3, 2019
Primary completionActual
Jan 21, 2020
CompletionActual
Jan 21, 2020
Last update
Jul 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04079413
Lead sponsor
Geropharm
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Jun 3, 2019
Primary completion
Jan 21, 2020
Completion
Jan 21, 2020
Last update
Jul 23, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion